ECSP15051434A - Composición farmacéutica de dosis baja - Google Patents
Composición farmacéutica de dosis bajaInfo
- Publication number
- ECSP15051434A ECSP15051434A ECIEPI201551434A ECPI201551434A ECSP15051434A EC SP15051434 A ECSP15051434 A EC SP15051434A EC IEPI201551434 A ECIEPI201551434 A EC IEPI201551434A EC PI201551434 A ECPI201551434 A EC PI201551434A EC SP15051434 A ECSP15051434 A EC SP15051434A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- deferasirox
- low dose
- dose pharmaceutical
- composition comprises
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención proporciona una composición farmacéutica de dosis baja que comprende deferasirox o un derivado farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables. Una dosis unitaria de la composición farmacéutica comprende desde aproximadamente 50 mg hasta aproximadamente 100 mg de deferasirox, desde aproximadamente 150 mg hasta aproximadamente 200 mg de deferasirox o desde aproximadamente 260 mg hasta aproximadamente 350 mg de deferasirox. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox, puede usarse para tratar sobrecarga de hierro crónica o para tratar toxicidad por plomo. La composición farmacéutica de la presente invención, en la que la composición farmacéutica comprende deferasirox y deferiprona, puede usarse para tratar toxicidad por plomo. Esta invención también proporciona un procedimiento para preparar la composición farmacéutica de dosis baja, comprendiendo el procedimiento: disolver o adsorber o combinar deferasirox y al menos un excipiente para producir una dispersión de deferasirox; y procesar la dispersión para producir una forma de dosificación deseada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1696MU2013 IN2013MU01696A (es) | 2013-05-10 | 2014-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP15051434A true ECSP15051434A (es) | 2017-05-31 |
Family
ID=50979804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201551434A ECSP15051434A (es) | 2013-05-10 | 2015-12-10 | Composición farmacéutica de dosis baja |
Country Status (18)
Country | Link |
---|---|
US (4) | US20160120847A1 (es) |
EP (1) | EP2994131A1 (es) |
JP (1) | JP2016518398A (es) |
CN (1) | CN105377256A (es) |
AP (1) | AP2015008875A0 (es) |
AU (1) | AU2014264421A1 (es) |
BR (1) | BR112015028257A2 (es) |
CA (1) | CA2911671A1 (es) |
EC (1) | ECSP15051434A (es) |
HK (1) | HK1215191A1 (es) |
IN (1) | IN2013MU01696A (es) |
MX (1) | MX2015015553A (es) |
PE (1) | PE20151934A1 (es) |
PH (1) | PH12015502557A1 (es) |
RU (1) | RU2015149544A (es) |
SG (1) | SG11201509308TA (es) |
WO (1) | WO2014181108A1 (es) |
ZA (1) | ZA201403276B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2989145A1 (en) | 2015-06-17 | 2016-12-22 | Dispersol Technologies, Llc | Improved formulations of deferasirox and methods of making the same |
RU2616267C1 (ru) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения |
US20190091204A1 (en) * | 2016-03-17 | 2019-03-28 | Lupin Limited | Compositions of deferasirox |
CN105853367B (zh) * | 2016-05-10 | 2019-07-12 | 广州加德恩医药有限公司 | 地拉罗司固体分散体的制备方法及其药物制剂 |
WO2018007956A1 (en) * | 2016-07-05 | 2018-01-11 | Jubilant Generics Limited | Immediate release pharmaceutical composition of iron chelating agents |
CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
MA50201A (fr) * | 2017-10-25 | 2021-04-28 | Chiesi Farm Spa | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants |
CN109646423A (zh) * | 2018-12-03 | 2019-04-19 | 泓博元生命科技(深圳)有限公司 | 含nadh的生物高分子纳米球及其制备方法与应用 |
CN115400088B (zh) * | 2022-09-06 | 2023-07-07 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
CN115154428B (zh) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
GB0408078D0 (en) | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
JP2009512652A (ja) | 2005-10-19 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | 安息香酸誘導体含有分散錠 |
WO2009016359A1 (en) * | 2007-07-27 | 2009-02-05 | Pliva Hrvatska D.O.O. | New forms of deferasirox |
EP2062572A1 (en) | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
PE20170468A1 (es) * | 2010-10-01 | 2017-04-26 | Cipla Ltd | Composicion farmaceutica que comprende deferasirox |
CA2846436A1 (en) * | 2011-09-23 | 2013-03-28 | Universitat Stuttgart | Serum half-life extension using immunoglobulin binding domains |
-
2014
- 2014-05-08 AU AU2014264421A patent/AU2014264421A1/en not_active Abandoned
- 2014-05-08 MX MX2015015553A patent/MX2015015553A/es unknown
- 2014-05-08 WO PCT/GB2014/051400 patent/WO2014181108A1/en active Application Filing
- 2014-05-08 ZA ZA2014/03276A patent/ZA201403276B/en unknown
- 2014-05-08 AP AP2015008875A patent/AP2015008875A0/xx unknown
- 2014-05-08 RU RU2015149544A patent/RU2015149544A/ru not_active Application Discontinuation
- 2014-05-08 IN IN1696MU2013 patent/IN2013MU01696A/en unknown
- 2014-05-08 SG SG11201509308TA patent/SG11201509308TA/en unknown
- 2014-05-08 US US14/890,235 patent/US20160120847A1/en not_active Abandoned
- 2014-05-08 BR BR112015028257A patent/BR112015028257A2/pt not_active IP Right Cessation
- 2014-05-08 PE PE2015002380A patent/PE20151934A1/es not_active Application Discontinuation
- 2014-05-08 JP JP2016512416A patent/JP2016518398A/ja active Pending
- 2014-05-08 CA CA2911671A patent/CA2911671A1/en not_active Abandoned
- 2014-05-08 CN CN201480038832.0A patent/CN105377256A/zh active Pending
- 2014-05-08 EP EP14731760.6A patent/EP2994131A1/en not_active Withdrawn
-
2015
- 2015-11-10 PH PH12015502557A patent/PH12015502557A1/en unknown
- 2015-12-10 EC ECIEPI201551434A patent/ECSP15051434A/es unknown
-
2016
- 2016-02-18 US US15/047,091 patent/US20160158202A1/en not_active Abandoned
- 2016-03-21 HK HK16103262.7A patent/HK1215191A1/zh unknown
- 2016-10-12 US US15/291,728 patent/US20170095453A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,195 patent/US20170312254A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016518398A (ja) | 2016-06-23 |
IN2013MU01696A (es) | 2015-06-26 |
US20160158202A1 (en) | 2016-06-09 |
PH12015502557A1 (en) | 2016-02-22 |
US20170312254A1 (en) | 2017-11-02 |
PE20151934A1 (es) | 2015-12-26 |
BR112015028257A2 (pt) | 2017-07-25 |
MX2015015553A (es) | 2016-06-17 |
SG11201509308TA (en) | 2015-12-30 |
HK1215191A1 (zh) | 2016-08-19 |
WO2014181108A1 (en) | 2014-11-13 |
US20170095453A1 (en) | 2017-04-06 |
RU2015149544A (ru) | 2017-06-16 |
ZA201403276B (en) | 2015-07-29 |
CN105377256A (zh) | 2016-03-02 |
AP2015008875A0 (en) | 2015-11-30 |
EP2994131A1 (en) | 2016-03-16 |
AU2014264421A1 (en) | 2015-12-03 |
CA2911671A1 (en) | 2014-11-13 |
US20160120847A1 (en) | 2016-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP15051434A (es) | Composición farmacéutica de dosis baja | |
DOP2019000201A (es) | Compuestos inhibidores del vih | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CO2020004301A2 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
EA202091169A1 (ru) | Применяемые в качестве ингибиторов iap миметики smac и их применение | |
BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
AR108792A1 (es) | Composiciones que comprenden timolol | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |